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Thirty-eight patients with surgically treated stage IB adenosquamous 
carcinoma of the uterine cervix (AS) have been matched with patients 
with other histologic subtypes of adenocarcinoma (A) for stage, lesion 
size, node status, grade of adenocarcinoma and age at diagnosis. An ad- 
ditional six patients with AS were unable to be matched. Overall 5-year 
survival and disease-free survival for the matched AS and A were not sig- 
nificantly different, 83 vs. 90%, and 78 vs. 81% nor were the number of 
recurrences, 8/38 AS vs. 6/38 A, but the mean time to recurrence was sig- 
nificantly shorter in the AS group: 11 vs. 32 months (P = 0.003). A sub- 
group of AS with a high risk of a poor outcome can be identified based on 
either lesion size > 4 cm, depth of invasion > 10 mm or plevic lymph 
node metastasis. These patients may be suitable candidates for adjuvant 
therapy before or after surgical treatment. 
KEYWORDS: adenocarcinoma, adenosquamous, carcinoma, cervix, pro- 
gnosis, survival. 
The significance of adenosquamous carcinoma (AS) as 
a separate sub-type of carcinoma of the cervix is still 
unclear. It is reported to represent approximately 30% 
of all adenocarcinomas of the cerv ix  (1-19) and up to 62% 
in individual series (6'7). Papers have been published in 
support of both a poor prognosis for AS (1"4-7'13'14'20-23) 
and a prognosis not significantly different from other 
types of adenocarcinoma (A) of squamous cell car- 
c inoma (SCC) (8-10'12'24) (Table 1). 
Address for correspondence: Dr C.W. Helm, Director, Division 
of Gynecologic Oncology, Department of Obstetrics and 
Gynecology, Temple University, Broad and Ontario Streets, 
Philadelphia, PA 19140, USA. 
A major problem with the assessment of outcome 
for this tumor is that reports may include a variety of 
histologic types ranging from tumors composed of 
malignant squamous and glandular elements clearly 
identifiable with hematoxylin and eosin stains, to 
poorly differentiated SCC in which the glandular ele- 
ment is only revealed by the use of mucin stains. De- 
spite the lack of agreement on the exact histologic 
criteria for AS many investigators do not even mention 
the actual criteria used in their studies (4'6'1°'12"22) which 
makes interpretation difficult. 
Many reports of the outcome for AS are based 
on the experience of single institutions with relatively 
small numbers of patients who have been only clin- 
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Table 1. Prognosis for adenosquamous carcinoma of the cervix 
AS or 'mixed' Include SCC with 
Author Year carcinoma Prognosis positive mucin 
Kilgore et al. (9) 1988 47 Same as A and SCC by stage no 
Korhonen (I°) 1984 40 Same as A overall * 
Rufledge et al.(12) 1975 25 Same as A overall * 
Hopkins et al.(S) 1988 66 Same as A overall and by stage no 
Benda et al. (32) 1985 18 Same as A and SCC yes 
Abell & Gosling (1) 1962 11 Worse than A and SCC no 
Kottmeier (23) 1964 153 Worse than A and SCC yes 
Swan & Roddick 04) 1973 20 Worse than A and SCC yes 
Davidson et al.(4) 1989 21 Worse than A and SCC * 
Gallup et al.(6) 1985 20 Worse than A and SCC overall and IB * 
Fu et al.(5) 1982 37 Worse than A overall and by stage * 
Glucksmann & Cherry (7) 1956 195 Worse than SCC yes 
Saigo et al.(13) 1986 20 Worse than endometrioid A no 
Wheeless et al.(2°) 1970 58 Worse than SCC yes 
Julian et al.(21) 1977 26 Worse than SCC * 
Adcock et a1.(22) 1982 26 Worse than SCC * 
Ireland et al.(36) 1985 18 Worse than SCC yes 
* = not mentioned. 
ically s taged.  To date,  14 publ icat ions  have  repor ted  
an  average  of 19 s tage I or IB AS t um or s  per  
s tudy  (4-7'9'11'13A5"21-23'25'26). On ly  six pape r s  have  re- 
por t ed  on surgically s taged I or IB pat ients  wi th  an 
average  of only  10 cases per  study (6"9'21'22'25'26) and sur- 
gical s taging is critical for precise clinico-pathologic 
invest igat ion.  
This s tudy  was  des igned  to invest igate  the ou tcome  
of a relat ively large n u m b e r  of pa t ien ts  wi th  stage IB, 
histologically conf i rmed,  AS in w h o m  the exact extent  
of disease had  been  surgically de t e rmined  in compar i -  
son  wi th  a g roup  of pa t ien ts  wi th  surgically t reated 
adenoca rc inomas  of o ther  histologic sub types  
ma t ched  for lesion size, pelvic l y m p h  node  status,  
g rade  of adenoca rc inoma  and  age. 
M a t e r i a l s  a n d  m e t h o d s  
Patients  wi th  clinical s tage IB a d e n o s q u a m o u s  car- 
c inoma of the cervix were  identif ied f rom the t u m o r  re- 
gistries of the Univers i ty  of A labama  at Bi rmingham,  
The Univers i ty  of Michigan,  A n n  Arbor  and  the Mayo  
Clinic, Rochester .  Clinical data  were  ob ta ined  f rom the 
individual  medical  records  and  whe re  appropr i a t e  by  
direct pa t ien t  contact.  The strict criteria for en t ry  into 
the s tudy  for bo th  a d e n o s q u a m o u s  and  adenocar -  
c inomas  were:  (i) disease surgically conf i rmed to be  
conf ined to the uter ine  cervix wi th  or wi thou t  l y m p h  
node  metas tas is ;  (ii) l y m p h  node  s tatus  conf i rmed by  
pelvic l y m p h a d e n e c t o m y ;  (iii) comple te  medical  rec- 
ords  and  pathologic  material;  (iv) histologic confirma- 
tion. The pat ients  wi th  AS were  ma tched  with  A for 
the fol lowing criteria: lesion size (greatest  d iameter  in 
cm), pelvic l y m p h  node  status,  architectural  grade  of 
the adenocarc inoma  and age at diagnosis.  The inten- 
tion was  to match  pat ients  t reated wi th in  the same 
center  where  possible.  Lesion size was  ma tched  to 
wi th in  0.5 cm be low 4 cm and  to wi th in  I cm above  4 
cm. Pelvic nodes  were  ma tched  by  posi t ive and  neg-  
ative and  by  n u m b e r  if posit ive,  g r a d e + l ,  and  age as 
closely as possible.  His to logy rev iew was  pe r fo rmed  
by  three his topathologis ts  (WDL, TSF, GK) sitting to- 
gether .  As par t  of a comple te  rev iew of all AS car- 
c inoma of the cervix t reated at the three inst i tut ions 
agreed  histologic criteria were  establ ished for the 
diagnosis  of AS as "a  t u m o r  which  contains obvious  
mal ignan t  g landular  and  s q u a m o u s  e lements  us ing  
conventional hematoxylin and eosin-staining. Glandu-  
lar e lements  are recognized by  overt  g land forma-  
tion or by  the presence  of ' s ignet  r ing '  cells. Squamous  
differentiation, as in pu re  s q u a m o u s  carcinoma of the 
cervix, is character ized by  either f rank kerat inizat ion 
or by  nests  of spindle  cells or large cells wi th  intercel- 
lular br idges" .  Glassy cell carcinoma is considered to 
be an  a d e n o s q u a m o u s  var iant  and  eligible pat ients  
were  included in the s tudy.  Glassy cell carcinoma was  
character ized as descr ibed by  Gl i icksman & Cher ry  (7) 
by  the presence  of " large cells containing a mode ra t e  
a m o u n t  of finely g ranu la r  cy toplasm,  which  gives 
them their characteristic ground-glass  appearance.  The 
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cytoplasm stains faintly blue with hematoxylin. The 
cells have a distinct cell wall, and the nuclei are prom- 
inent and contain prominent nucleoli". No special 
stains were included in the criteria. Only patients with 
definite carcinoma of the uterine cervix were induded.  
The definition of adenocarcinoma included all other 
recognized forms of adenocarcinoma as described by 
Blaustein (27), including columnar cell (endocervical), 
colloid, endometrioid, papillary serous and clear cell, 
adenoid cystic and mesonephric sub-types. 
In the adenocarcinomatous elements grading was 
based on the architectural pattern: a well-differen- 
tiated tumor contained well-formed simple glands, 
moderately differentiated was characterized by inter- 
branching glands and variable amounts of intracyto- 
plasmic mucin which may show a cribriform pattern 
and a poorly differentiated contained sheets of cells 
with only focal gland formation. A well-differentiated 
squamous cell carcinoma was characterized by mature 
cells with abundant eosinophilic cytoplasm with or 
without abundant keratin with keratin pearls and in- 
dividual cell keratinization (dyskeratosis). Cells were 
usually tightly packed together with well-developed 
intercellular bridges. Moderately well-differentiated 
neoplastic ceils were more pleomorphic with large 
irregular nudei,  less abundant cytoplasmic matrix and 
more numerous mitotic figures. The cellular borders 
as well as intercellular bridges were indistinct. Keratin 
pearl formation was virtually non-existent and in- 
dividual cell keratinization present in the center of 
nests of tumor cells. 
Poorly differentiated tumors contained abundant 
mitoses and areas of necrosis. The cells contained 
hyperchromatic oval nuclei and scant indistinct cyto- 
plasm. There were rare foci of abortive dyskeratosis 
only. Depth of invasion was measured as the thick- 
ness of the tumor in a plane perpendicular to the adja- 
cent epithelium. 
Statistical analysis was performed in the Division of 
Biostatistics, Comprehensive Cancer Center, University 
of Alabama at Birmingham. Survival curves were cal- 
culated according to the method of Kaplan and Meier 
with differences compared using the log rank test. The 
t-tests and Chi-square tests were used as appropriate. 
Results 
Ninety-two patients were initially thought to be eli- 
gible for inclusion but 48 patients were excluded be- 
cause they did not meet the strict entry criteria for the 
following reasons: histology not adenosquamous on 
review (n = 32), incomplete clinical data (n = 3), insuf- 
ficient histologic material (n = 10) and surgical stage 
Table 2. Details of matching data 
AS Adenocarcinoma 
n = 38 n = 38 
Lesion size 
1-1.9 11 12 
2-2.9 9 8 
3-3.9 10 10 
~- 4cm 8 8 
Pelvic lymph node status 
0 34 34 
1 3 2 
2 1 2 
Grade 
Well 3 9 
Moderate 22 21 
Poor 13 8 
Age 
20-29 7 3 
30-39 10 11 
40-49 16 15 
>50 5 9 
other than IB (n = 4). These four patients had tumor 
extension outside the cervix, vagina (1), parametrium 
(2), paracervical tissues (1). Additionally, two patients 
initially thought to be stage IB adenocarcinoma but 
found on histology review to be AS had disease ex- 
tension outside the cervix at surgery into the paramet- 
rium (1) and vagina (1). 
Forty-four patients met the entry criteria. It was not 
possible to match six AS patients. Five of these pa- 
tients had positive lymph nodes in association with a 
lesion size between 2 and 4 cm and one had a lesion 
size of 8 cm with negative nodes. One patient in the AS 
group had a glassy cell tumor and another had glassy 
cell elements. Thirty-eight patients with AS were 
matched one-for-one with 38 patients with A by the 
study criteria (Table 2). The average age of the 
matched AS and A groups was 41 years (range 22-63 
years) and 43 years (range 26-73 years). Complete pel- 
vic lymphadenectomy was performed in 36 patients in 
each group with sampling of the pelvic nodes in two 
cases each. Sampling of the paraaortic nodes was per- 
formed in 15 AS and 12 A and all were negative for 
metastasis. Peritoneal washings were examined cyto- 
logically in 19 AS and 14 A and in all cases were neg- 
ative for malignant cells. 
All 38 patients with AS underwent  radical hysterec- 
tomy with five receiving postoperative radiotherapy. 
In the A group, 35 patients underwent  radical hys- 
terectomy with four receiving postoperative RT. Three 
A patients underwent total abdominal hysterectomy 
and staging laparatomy one following preoperative 
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Fig. 1. Survival for matched AS and A and  unmatched  AS. 
RT. All three underwent  postoperative RT. The 
matched group of adenocarcinomas included the fol- 
lowing subtypes: endocervical (33), colloid (2), papil- 
lary (1), endometrioid (1) and adenoid cystic (1). 
The 5-year survival for the 38 matched AS patients 
was 83 vs. 90% for the A (P = 0.275 for comparison 
of the two survival curves, Fig. 1). For the 34 patients 
in each group with negative nodes the 5-year survival 
was 84% AS and 93% A (P = 0.225). Of the four 
matched AS patients with positive nodes one is dead 
of disease, one is lost to follow-up after experiencing 
a vaginal vault recurrence and two are alive and well 
at 126 and 106 months. Of the four matched A with 
positive nodes one is dead of disease, one is dead of 
another cause, one is alive with recurrence and one 
is alive and free of disease at 62 months. The overall 
disease-free survival was not significantly different be- 
tween the matched groups 78% AS: 81% A (P = 0.522 
for the comparison of the two disease-free survival 
curves, Fig. 2) but the average time to recurrence was 
significantly shorter for the AS patients, 11 vs. 36 
months (P = 0.03). 
Eight (25%) patients in the matched AS group re- 
curred, four in the pelvis alone, three pelvis and dis- 
tant, and one distant only. Six of the eight patients 
who recurred died of carcinoma of the cervix. Two 
other patients hac~ recurrence in the vaginal vault, one 
surviving after treatment and the other lost to follow- 
up before treatment. Six of the matched A recurred 
with the sites being pelvis alone (2), pelvis and distant 
(1) and distant (3). 
No patient with either AS or A recurred or died fol- 
lowing treatment for the primary tumor with a depth 
of invasion < 1.0 cm (Fig. 3). In the matched AS group 
8 of 15 (53%) patients with depth of invasion ~ 1 cm 
recurred as opposed to 6 of 15 A (40%). Of these 15 A 
patients four had positive nodes and three recurred 
and three of 11 with negative nodes recurred. When all 
the AS are examined 10 of 20 (50%) with depth of inva- 
sion ~ 1 cm recurred, six of the 20 had positive nodes 
and four recurred whilst six of 14 with negative nodes 
recurred. 
In the matched study no AS or A patients were 
pregnant at the time of diagnosis but two of the 
unmatched AS patients were pregnant at 28 and 35 
weeks and both were treated with Caesarean hysterec- 
tomy and postoperative radiotherapy. One of these 
patients had two positive pelvic nodes and is alive 
without recurrence at 130 months and the other with 
one positive node is dead of disease at 8 months. 
Survival was significantly better for those matched 
AS with lesion size <: 2 cm when compared with 
those -> 4 cm (P = 0.025). The 44 patients with AS (in- 
cluding the unmatched patients) were divided into 
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Fig. 2. Disease-free survival for matched A and As and unmatched AS. 
two groups based on node positivity, lesion size > 4 
cm or depth of invasion > 1 cm and anlysis revealed 
25 AS patients with a significantly higher risk for 
recurrence (Fig. 4). 
Discuss ion 
Debate about the significance of adenosquamous 
carcinoma of the cervix has been dogged by a failure of 
researchers to adhere to either a uniform name or uni- 
form histologic criteria for the tumor. At least five 
different terms have been applied to describe tumors 
containing both squamous and glandular elements 
including pseudo-epidermoid (28), mixed carcinoma (7), 
mucoepidermoid (29), acantho-adenocarcinoma °), ad- 
enoepidermoid (2°) and adenosquamous (21). 
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Table 3. Significant factors not included in matching 
AS Adenocarcinoma 
Depth of invasion 
< 2.9mm 0 3 
3-6.9 10 16 
7-9.9mm 12 3 
10-19.9mm 12 11 
-> 20mm 3 4 
Unknown 1 1 
Overall grade 
Well 1 9 
Moderate 18 21 
Poor 19 8 
The main  area of content ion  is whe the r  or not  to in- 
clude tumors  which  do  not  contain obvious squamous  
and  glandular  e lements  on convent ional  hematoxyl in  
and  eosin (H&E) stains but  which contain areas or cells 
which stain posit ive for mucin  with special stains. It 
has been  repor ted  that such tumors  have a worse  
prognosis ,  or worse  prognost ic  features,  than  pure  
squamous  cell carcinomas with no  mucin  positive 
cells (23"30'31) a l though others  repor t  no  significant dif- 
ference in survival (32). Some investigators include such 
pat ients  in series of adenosquamous  ca rdnomas  (7A4'2°) 
and  repor t  a worse  ou tcome over  ei ther  pure  SCC (7'2°) 
or o ther  forms of A and SCC 04) (Table 1). The inclusion 
of pat ients  with squamous  cell carcinoma and mucin 
staining produces  an uncer ta inty  with regard to the ac- 
tual am o u n t  of mucin  staining required to change the 
classification of a n  S C C  (29"30) and makes interpretat ion 
difficult. 
We decided to restrict the histologic criteria to those 
features which are readily definable by  routine H&E 
staining wi thout  resort  to special stains in order  to ob- 
tain a h o m o g e n e o u s  group  for study.  The difficulties 
associated with the diagnosis of AS carcinoma are 
exemplified by the fact that 32 (35%) patients origin- 
ally d iagnosed with AS were  excluded from the s tudy 
because on  review of the histology they were con- 
sidered not  to have AS at all. Seventeen were reclas- 
sified as adenocarcinomas,  14 as SCC and one as an 
adenoid  basal carcinoma. Despite these exclusions, 
this is the largest series of surgically staged IB adeno- 
squamous  carcinoma of the cervix so far reported.  
The process of matching patients with those with 
adenocarc inoma of o ther  histologic types allows for a 
stricter compar ison of both  prognosis  and prognostic 
features than would otherwise be possible. The match- 
ing criteria were selected because the features had been 
previously shown to be significant with regard to pro- 
gnosis of either carcinoma of the cervix in general, ad- 
enocarcinoma or AS; lesion size (13'15'18'33-35), lymph 
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node  s ta tus  (9'24'36'~7), t u m o r  grade (s'8-1°'ls'18"3s'36"3a'39) 
and  age (9'4°). 
O u r  pat ients  wi th  AS carc inoma stage IB did  have  a 
worse  survival  than  the m a t ched  g roup  of o ther  types  
of A (83 vs. 90%) bu t  the difference was  not  signifi- 
cantly different  overall.  H o w e v e r ,  o ther  factors in- 
dicate that  a sub -g roup  of AS tumors  do  have  a more  
aggress ive  tendency.  The  disease-free interval,  a 
measu re  of the t ime to first recurrence,  was  signi- 
ficantly shor ter  in the AS group;  the fact that  five 
pat ients  wi th  metas tases  to pelvic l y m p h  nodes  in as- 
sociation wi th  relat ively small  lesion size could not  be  
ma tched  wi th  adenocarc inomas ;  a h igher  incidence of 
poo r  grade  ei ther  of the  adenoca rc inoma  c o m p o n e n t  
or  overall  and  the greater  incidence of pa t ients  u n d e r  
30 years  of age. Dep th  of invas ion  of the p r i ma ry  
t u m o r  was  not  inc luded in our  ma tch ing  criteria bu t  
has  b e e n  r epor t ed  to be  associated wi th  a worse  out-  
come in adenoca rc inoma  ~z13'24'25) and  our  data wou ld  
agree  wi th  this view.  
In s u m m a r y ,  our  data  demons t r a t e  that  early stage 
a d e n o s q u a m o u s  carc inoma of the cervix affords the 
pa t ien t  a l ikelihood of survival  not  significantly dif- 
ferent  f rom an  adenocarc inoma  of similar size and  ex- 
tent  of spread.  Howe ve r ,  the f u n d a m e n t a l  differences 
in t u m o r  biology b e t w e e n  these  two  cell types  are 
man i fes t ed  in the marked l y  shor ter  t ime to recurrence  
obse rved  in a d e n o s q u a m o u s  pat ients ,  and  in the 
p ropens i ty  for noda l  metas tas is  of  a d e n o s q u a m o u s  
cancers of smaller  size which  p r e v e n t e d  match ing  of 
three out  of eight of the node  posi t ive a d e n o s q u a m o u s  
tumors  wi th  a greatest  d imens ion  of _< 4 cm. 
The data  also indicate that  a distinct sub -g roup  of AS 
carc inoma can be identified based  on  ei ther  lesion 
size > 4 cm, dep th  of invas ion > 10 m m  or node  
posi t ivi ty  w h o  are at a m u c h  higher  risk of ear ly re- 
currence  and  p o o r  survival.  We feel that  considera t ion 
should  be  g iven to some  fo rm of ad juvan t  chemo-  
radiat ion before  or after p r i m a ry  surgery  for this 
group.  
Conclusion 
There  is a sub -g roup  of AS w h o  have  a more  ag- 
gressive t u m o r  wi th  a shor ter  t ime to recurrence and  
poore r  p rognos i s  t han  m a t ched  adenocarc inomas .  
This g roup  includes pat ients  wi th  posi t ive pelvic 
l y m p h  nodes,  lesion size ___ 4 cm and  dep th  of inva- 
sion into the cervix of > 10 m m .  Considera t ion  should  
be  g iven to ad juvan t  chemo-i r radia t ion  for this group.  
Converse ly ,  a g r o u p  of pa t ien ts  wi th  AS w h o  have  a 
good  prognos i s  can be identif ied by  surgical staging. 
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